Ex­perts of­fer a sol­id en­dorse­ment for Acel­Rx pain med, spurring a big ral­ly for their stock

The FDA forced Acel­Rx Phar­ma­ceu­ti­cals to go back to the draw­ing board to re­fash­ion a bet­ter safe­ty plan for its new pain ther­a­py Dsu­via …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.